Therapeutic Drug Monitoring and Pharmacogenetic Tests as Tools in Pharmacovigilance of Anti Parkinson’s Therapy
Objective: Parkinson's disease (PD) is the second most prevalent neurodegenerative disease worldwide, affecting more than 7 million people worldwide. However, treatment outcome in many patients…Ondansetron, a highly-selective 5-HT3 receptor antagonist, alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To determine the effectiveness of selective serotonin 3 (5-HT3) receptor blockade at reducing the severity of established, and preventing the development of, dyskinesia. Background:…Association between serum Vitamin D levels and Parkinson’s disease: A systematic review and meta-analysis
Objective: The aim of this systematic review and meta-analysis was to evaluate the association between serum vitamin D levels and the risk and severity of…Effect of dopamine agonists versus levodopa as initial treatment in Parkinson’s Disease
Objective: We evaluated the efficacy of different starting drugs in the treatment of Parkinson's disease (PD), in order to further explore the initial therapy of…Pilot study of a new tool to optimize dopaminergic treatment in Parkinson’s disease: The OPTIPARK Scale Project
Objective: Our objective was to develop and pilot test a scale (OPTIPARK) for assessing a patient´s dopaminergic state, allowing the clinician to consider the adjustment…The highly selective 5-HT2A receptor antagonist EMD-281,014 alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To investigate the effect of the highly-selective serotonin 2A (5-HT2A ) receptor antagonist EMD-281,014 at alleviating L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia in the 6-hydroxydopamine (6-OHDA)-lesioned rat.…Quantifying the Reproducibility of an In Vivo Assay: Examination of Historical Amantadine Effects in the macaque Model of L-DOPA-Induced Dyskinesia
Objective: This study was designed to assess the reproducibility of the amantadine anti-dyskinetic effect in the MPTP L-DOPA-Induced Dyskinesia (LID) macaque model for soundly defining…Impact of Age on Levodopa dosage regimes in Idiopathic Parkinson’s Disease
Objective: To assess the influence of patient age on prescribed dosage and subsequent dose escalation regimes of levodopa therapy in a cohort of people with…A first-in-human clinical study to test the safety and preliminary efficacy of CDNF in Parkinson’s disease
Objective: To develop a novel disease-modifying therapy in Parkinson's disease (PD) that affects both motor and non-motor symptoms, based on a novel stress-protective protein CDNF.…Implementation and Validation of a Biometric Solution for Remote Monitoring of Motor Symptoms in Patients with Huntington Disease in a Phase II Clinical Trial
Objective: To implement and validate quantification of motor dysfunction in a Huntington disease (HD) clinical trial using machine learning algorithmic analysis derived from biometric monitoring…
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- …
- 32
- Next Page »